Body Weight

A combination GLP-1/amylin analog conferred a superior reduction in body weight at 68 weeks vs. placebo for adults with obesity or overweight with at least one weight-related comorbidity, according to top-line results from a phase 3 trial.

SAN DIEGO — Semaglutide was superior to placebo in metabolic dysfunction-associated steatohepatitis resolution and improvement in fibrosis at 72 weeks, with a safety profile consistent with previous studies, according to late-breaking data.

BOSTON — Adults who experienced BMI or weight gains between age 2 years and 5 years, as well as after age 11 years, faced increased odds for high obstructive sleep apnea risk, according to data presented at the CHEST Annual Meeting.

Adults with type 1 diabetes using either semaglutide or tirzepatide off-label had greater decreases in body weight and HbA1c than those not treated with either medication, according to a speaker.

A once-weekly GLP-1/glucagon dual agonist conferred greater decreases in HbA1c and body weight than the GLP-1 receptor agonist dulaglutide for adults with type 2 diabetes, according to a presenter.

Exposure to higher amounts of some types of per- and polyfluoroalkyl substances during pregnancy may lead to long-term increases in body weight, waist circumference and fat mass, according to new findings.

Adults with obesity and type 2 diabetes had reductions in body weight and HbA1c 1 year after undergoing an endoscopic procedure that resurfaces the duodenum lining, according to top-line results from a real-world registry study.

Women with polycystic ovary syndrome are more likely to have any form of disordered eating, particularly bulimia or binge eating disorder, suggesting a weight-neutral treatment plan could be beneficial, data show.